Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer
H. Hausmaninger(Unfallkrankenhaus Salzburg), Georg Kemmler(Innsbruck Medical University), Renate Haidinger, Guenther G. Steger(Mount Vernon Hospital), G. Tschurtschenthaler, L. Schiller, M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Fridrik, R. Kienzer(Kaiser-Franz-Josef-Spital), P. Sevelda, D. Manfreda, H. Samonigg(Wilhelminen Hospital), W. Hehenwarter
Cited by 11
Related Papers
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799